We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Doric Nimrod Air One Limited | LSE:DNA | London | Ordinary Share | GG00B4MF3899 | ORD PRF SHS NPV |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 60.00 | 59.00 | 61.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2019 to May 2024
Chugai Pharmaceutical Co. (4519.TO) said Wednesday that it is undeniable that its rheumatoid arthritis drug Actemra might be a causal factor in the deaths of 15 patients.
According to research of 4,915 cases conducted by the doctors who prescribed the drug, heavy side effects were found in 221 cases, and 15 deaths were undeniably connected to the drug during the 10 months to February, a Chugai spokesman said.
The spokesman said that the company will provide more information so that doctors can have a better understanding of the drug's side effects.
Actemra was approved in April in Japan last year, but in order to verify side effects undetected by clinical tests, the Health Ministry requested an investigation of all patients who have taken it.
The drug is also currently under regulatory review by the U.S. Food and Drug Administration.
-By Yoshio Takahashi, Dow Jones Newswires; 813-5255-2929; yoshio.takahashi@dowjones.com
1 Year Doric Nimrod Air One Chart |
1 Month Doric Nimrod Air One Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
